Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: Implications for the treatment of low-grade adult and pediatric brain tumors

William J. Bodell, Nilesh W. Gaikwad, Douglas Miller, Mitchel S. Berger

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors. Treatment of patients with alkylating chemotherapeutic agents has been established to increase their risk for acute myelogenous leukemia. The formation of DNA adducts and induction of mutations are likely to play a role in the etiology of therapy-related acute myeloid leukemia. To evaluate this issue for TMZ, we have measured the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with TMZ. Treatment of Big Blue Rat-2 cells with either 0, 0.5, or 1 mM TMZ resulted in lacI mutant frequencies of 9.1 ± 2.9 × 10-5, 48.9 ± 12 × 10-5, and 89.7 ± 40.3 × 10-5, respectively. Comparison of the mutant frequencies demonstrated that 0.5 and 1 mm TMZ treatments increased the mutant frequencies by 5.3- and 9.8-fold and that this increase was significant (P < 0.001). Sequence analysis of the lacI mutants from the TMZ treatment group demonstrated that they were GC → AT transitions at non-CpG sites, which is significantly different from the mutation spectrum observed in the control treatment group. Treatment of Big Blue Rat-2 cells with various concentrations of TMZ produced a linear increase in the levels of N7-methylguanine and O6-methylguanine. The IacI mutation spectrum induced by TMZ treatment is consistent with these mutations being produced by O6-MeG. This study establishes TMZ has significant mutagenic potential and suggests that careful consideration in the use of TMZ for the treatment of low-grade adult and pediatric brain tumors should be given.

Original languageEnglish (US)
Pages (from-to)545-551
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume12
Issue number6
StatePublished - Jun 1 2003

Fingerprint

temozolomide
DNA Adducts
Brain Neoplasms
Pediatrics
Mutation
Therapeutics
Acute Myeloid Leukemia
Alkylating Agents

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide : Implications for the treatment of low-grade adult and pediatric brain tumors. / Bodell, William J.; Gaikwad, Nilesh W.; Miller, Douglas; Berger, Mitchel S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 12, No. 6, 01.06.2003, p. 545-551.

Research output: Contribution to journalArticle

@article{a0a7db0b8baf46f6a9aec6907c54a566,
title = "Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: Implications for the treatment of low-grade adult and pediatric brain tumors",
abstract = "Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors. Treatment of patients with alkylating chemotherapeutic agents has been established to increase their risk for acute myelogenous leukemia. The formation of DNA adducts and induction of mutations are likely to play a role in the etiology of therapy-related acute myeloid leukemia. To evaluate this issue for TMZ, we have measured the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with TMZ. Treatment of Big Blue Rat-2 cells with either 0, 0.5, or 1 mM TMZ resulted in lacI mutant frequencies of 9.1 ± 2.9 × 10-5, 48.9 ± 12 × 10-5, and 89.7 ± 40.3 × 10-5, respectively. Comparison of the mutant frequencies demonstrated that 0.5 and 1 mm TMZ treatments increased the mutant frequencies by 5.3- and 9.8-fold and that this increase was significant (P < 0.001). Sequence analysis of the lacI mutants from the TMZ treatment group demonstrated that they were GC → AT transitions at non-CpG sites, which is significantly different from the mutation spectrum observed in the control treatment group. Treatment of Big Blue Rat-2 cells with various concentrations of TMZ produced a linear increase in the levels of N7-methylguanine and O6-methylguanine. The IacI mutation spectrum induced by TMZ treatment is consistent with these mutations being produced by O6-MeG. This study establishes TMZ has significant mutagenic potential and suggests that careful consideration in the use of TMZ for the treatment of low-grade adult and pediatric brain tumors should be given.",
author = "Bodell, {William J.} and Gaikwad, {Nilesh W.} and Douglas Miller and Berger, {Mitchel S.}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "12",
pages = "545--551",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide

T2 - Implications for the treatment of low-grade adult and pediatric brain tumors

AU - Bodell, William J.

AU - Gaikwad, Nilesh W.

AU - Miller, Douglas

AU - Berger, Mitchel S.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors. Treatment of patients with alkylating chemotherapeutic agents has been established to increase their risk for acute myelogenous leukemia. The formation of DNA adducts and induction of mutations are likely to play a role in the etiology of therapy-related acute myeloid leukemia. To evaluate this issue for TMZ, we have measured the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with TMZ. Treatment of Big Blue Rat-2 cells with either 0, 0.5, or 1 mM TMZ resulted in lacI mutant frequencies of 9.1 ± 2.9 × 10-5, 48.9 ± 12 × 10-5, and 89.7 ± 40.3 × 10-5, respectively. Comparison of the mutant frequencies demonstrated that 0.5 and 1 mm TMZ treatments increased the mutant frequencies by 5.3- and 9.8-fold and that this increase was significant (P < 0.001). Sequence analysis of the lacI mutants from the TMZ treatment group demonstrated that they were GC → AT transitions at non-CpG sites, which is significantly different from the mutation spectrum observed in the control treatment group. Treatment of Big Blue Rat-2 cells with various concentrations of TMZ produced a linear increase in the levels of N7-methylguanine and O6-methylguanine. The IacI mutation spectrum induced by TMZ treatment is consistent with these mutations being produced by O6-MeG. This study establishes TMZ has significant mutagenic potential and suggests that careful consideration in the use of TMZ for the treatment of low-grade adult and pediatric brain tumors should be given.

AB - Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors. Treatment of patients with alkylating chemotherapeutic agents has been established to increase their risk for acute myelogenous leukemia. The formation of DNA adducts and induction of mutations are likely to play a role in the etiology of therapy-related acute myeloid leukemia. To evaluate this issue for TMZ, we have measured the formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with TMZ. Treatment of Big Blue Rat-2 cells with either 0, 0.5, or 1 mM TMZ resulted in lacI mutant frequencies of 9.1 ± 2.9 × 10-5, 48.9 ± 12 × 10-5, and 89.7 ± 40.3 × 10-5, respectively. Comparison of the mutant frequencies demonstrated that 0.5 and 1 mm TMZ treatments increased the mutant frequencies by 5.3- and 9.8-fold and that this increase was significant (P < 0.001). Sequence analysis of the lacI mutants from the TMZ treatment group demonstrated that they were GC → AT transitions at non-CpG sites, which is significantly different from the mutation spectrum observed in the control treatment group. Treatment of Big Blue Rat-2 cells with various concentrations of TMZ produced a linear increase in the levels of N7-methylguanine and O6-methylguanine. The IacI mutation spectrum induced by TMZ treatment is consistent with these mutations being produced by O6-MeG. This study establishes TMZ has significant mutagenic potential and suggests that careful consideration in the use of TMZ for the treatment of low-grade adult and pediatric brain tumors should be given.

UR - http://www.scopus.com/inward/record.url?scp=0038119669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038119669&partnerID=8YFLogxK

M3 - Article

C2 - 12815001

AN - SCOPUS:0038119669

VL - 12

SP - 545

EP - 551

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -